Femme et Homme
- | Pays :
- Australia
- Germany
- Italy
- Les 3 autres...
- | Organes : -
- | Spécialités : -
Extrait
This study is designed to assess the efficacy, pharmacokinetics, safety, and tolerability of an oral, twice daily dose of 150 mg GSK2118436 administered to subjects with BRAF V600E or V600K mutation-positive metastatic melanoma to the brain. Subjects in Cohort A will not have received any local brain therapy, and subjects in Cohort B will have received prior local therapy for brain metastases. Subjects will continue on treatment until disease progression, death, or unacceptable adverse event.
Critère d'inclusion
- Melanoma and Brain Metastases